| Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. | |
| | |
MedLine Citation:
|
PMID: 22334369 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONCLUSION: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone. |
| | |
Authors:
|
Stephen A Harrison; Fayez M Hamzeh; Jian Han; Prashant K Pandya; Muhammed Y Sheikh; John M Vierling |
Related Documents
:
|
22796579 - Selective hepatic insulin resistance, very-low-density lipoprotein hypersecretion and h... 9496559 - Effect of octreotide on growth hormone, igf-i, igfbp-3, glucagon, cortisol and epinephr... 2887309 - On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients... 20946269 - A comparison of intermediate and long-acting insulins in people with type 2 diabetes st... 11251679 - No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration... 6246699 - Panhypopituitarism secondary to head trauma: evidence for a hypothalamic origin of the ... 20068149 - Insulin-mediated acceleration of breast cancer development and progression in a nonobes... 17192339 - Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. 16625819 - Pathological mechanisms involved in diabetic neuropathy: can we slow the process? |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2012-06-11 |
Journal Detail:
|
Title: Hepatology (Baltimore, Md.) Volume: 56 ISSN: 1527-3350 ISO Abbreviation: Hepatology Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-07-26 Completed Date: 2012-10-11 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 8302946 Medline TA: Hepatology Country: United States |
Other Details:
|
Languages: eng Pagination: 464-73 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 American Association for the Study of Liver Diseases. |
Affiliation:
|
Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA. STEPHEN.A.HARRISON@us.army.mil |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / administration & dosage, adverse effects Diabetes Mellitus, Type 2 / drug therapy, epidemiology Drug Therapy, Combination Female Follow-Up Studies Genotype Hepacivirus / drug effects*, genetics Hepatitis C, Chronic / drug therapy*, epidemiology, virology Humans Hypoglycemic Agents / administration & dosage, adverse effects Insulin Resistance / physiology* Interferon-alpha / administration & dosage*, adverse effects Liver Cirrhosis / epidemiology, virology Male Middle Aged Polyethylene Glycols / administration & dosage*, adverse effects Recombinant Proteins / administration & dosage, adverse effects Ribavirin / administration & dosage*, adverse effects Risk Factors Thiazolidinediones / administration & dosage*, adverse effects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Hypoglycemic Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/Thiazolidinediones; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; X4OV71U42S/pioglitazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ZnO Coaxial Nanorod Homojunction UV Light-Emitting Diodes Prepared by Aqueous Solution Method.
Next Document: Next-generation genetic testing for retinitis pigmentosa.